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Abstract
Background: Accurate and economic detection of nerve damage in diabetes is key to more widespread diagnosis
of patients with diabetic peripheral neuropathy (DPN) and painful diabetic neuropathy. This study examined the
diagnostic performance of NerveCheck, an inexpensive ($500) quantitative sensory testing (QST) device.
Methods: One hundred forty-four subjects (74 with and 70 without diabetes) underwent assessment with
NerveCheck, neuropathy disability score (NDS), nerve conduction studies (NCS), intraepidermal and corneal
nerve fiber density (IENFD and CNFD), and McGill questionnaire for neuropathic pain.
Results: Of the 74 subjects with diabetes, 41 were diagnosed with DPN based on the NDS. The NerveCheck
scores for vibration perception threshold (VPT), cold perception threshold (CPT), and warm perception
threshold (WPT) were significantly lower (P £ 0.0001) in diabetic patients with DPN compared to patients
without DPN. The diagnostic accuracy of VPT was high with reference to NCS (area under the curve [AUC]:
82%–84%) and moderate for IENFD, CNFD, and neuropathic pain (AUC: 60%–76%). The diagnostic accuracy
of CPT and WPT was moderate with reference to NCS, IENFD, and CNFD (AUC: 69%–78%) and low for
neuropathic pain (AUC: 63%–65%).
Conclusions: NerveCheck is a low-cost QST device with good diagnostic utility for identifying sensory deficits,
comparable to established tests of large and small fiber neuropathy and for the severity of neuropathic pain.
Keywords: NerveCheck, Quantitative sensory testing, Diabetic peripheral neuropathy, Diagnostic device.
Introduction
The prevalence of diabetic peripheral neuropathy(DPN) has been reported to be up to 50%.1,2 About half
of the people with DPN are affected by asymptomatic neu-
ropathy,3 and therefore, an absence of symptoms does not
mean an absence of DPN. Indeed neuropathy is central to the
development of painful neuropathy and foot ulceration in
patients with diabetes.4,5 Hence, it is important to identify
early sensory deficits in patients with diabetes to improve the
risk factors and limit the development and progression of
DPN. Both sensory deficits and altered thresholds for sensory
stimuli can be measured reliably using quantitative sensory
testing (QST).6 A loss of vibration sensation is related to
large fiber neuropathy,7 while loss of thermal sensation is
related to small fiber neuropathy. Indeed, QST assessment
has been endorsed for the quantification of sensory deficits by
the NeuPSIG consensus,7 and the diagnosis of neuropathic
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pain relies on a combination of positive neuropathic symp-
toms and sensory deficits as well as evoked pain.8 However,
QST is subjective and the devices used to undertake the as-
sessment are relatively expensive ($15,000) and therefore not
widely used in daily clinical practice.
NerveCheck is an inexpensive ($500), portable QST device
that measures the vibration perception threshold (VPT), cold
perception threshold (CPT), warm perception threshold (WPT),
and the heat pain threshold (HPT) of the patient. It uses the
method of levels where a series of predefined stimuli are applied
over a broad range of intensities to produce a categorical output
and define the severity of neuropathy. We have recently shown
that it has good reproducibility and comparable diagnostic ac-
curacy to established QST equipment for the diagnosis of
DPN.9 It can also accurately identify sensory deficits to help in
the identification of patients with painful diabetic neuropathy.10
Objective tests of small fiber neuropathy include structural
loss of small nerve fibers detected by corneal confocal mi-
croscopy (CCM) in the eye and intraepidermal nerve fiber
density (IENFD) in skin biopsies taken from the foot.11–13
In the present study, we have assessed the diagnostic utility
of NerveCheck for detecting both large and small fiber neu-
ropathy by comparing its diagnostic performance against
nerve conduction studies (NCS), CCM, IENFD, and severity
of painful diabetic neuropathy.
Research Design and Methods
Participants in the study were recruited from the Man-
chester Diabetes Centre, Manchester Royal Infirmary in
Manchester, United Kingdom. The study was performed at
the NIHR Wellcome Trust Clinical Research Facility be-
tween January 7, 2013 and September 19, 2014. Exclusion
criteria included subjects with communication disorders,
cognitive deficits, severe anxiety, severe depression, or history
of neuropathy due to a nondiabetic cause. Control subjects
with diabetes or suffering from any acute or chronic pain
condition were excluded. All subjects were without any pain
medication for at least 24 h before the investigation. This study
was approved by the Local Research Ethics committee, and all
patients gave informed consent to take part in the study. The
research adhered to the tenets of the declaration of Helsinki.
Demographic measures
All study participants underwent assessment of glycated
hemoglobin (HbA1c), body mass index (BMI), blood pres-
sure, and cholesterol.
Quantitative sensory testing
Subjects were familiarized with the procedure and allowed to
acclimatize for 10 min in the examination room.9 NerveCheck
(Phi Med Europe S.L., Barcelona, Spain) applies the method of
levels for a series of predefined stimuli (vibration intensity and
heat waveform), and the method of limits for ramped stimuli
(1C/s) to the skin and, for each stimulus, the subject has to
report when the stimulus is perceived to establish the VPT,
CPT, and WPT or whether it is painful or not for the HPT. The
output is categorical in terms of the degree of abnormality. The
normal and abnormal range for VPT is 12–8 and 7–0 and for
CPT and WPT is 6–3 and 2–0. More information about the
NerveCheck can be found online (www.phimedeurope.com).
Nerve conduction studies
Electrodiagnostic studies were undertaken using a Dantec
‘‘Keypoint’’ system (Dantec Dynamics Ltd., Bristol, United
Kingdom) equipped with a DISA temperature regulator to
keep lower limb temperature constantly between 32C and
35C. Sural nerve conduction velocity (SNCV), sural nerve
action potential (SNAP), and peroneal motor nerve conduc-
tion velocity (PMNCV) were assessed in the right lower limb
by a consultant neurophysiologist.
Corneal confocal microscopy
Patients underwent examination with the Heidelberg Re-
tina Tomograph (HRT III RCM) in vivo corneal confocal
microscope (Heidelberg Engineering GmbH, Heidelberg,
Germany) using our established methodology.14 Corneal
nerve fiber density (CNFD), the total number of nerve fibers
(No./mm2), corneal nerve branch density, the total number of
nerve branches (No./mm2), corneal nerve fiber length, and
the total length of all nerve fibers and branches (mm/mm2)
captured within the area of cornea were quantified from *5
adjacent images/subject using the ACCMetrics, an auto-
mated image analysis software.14 ACCMetrics is available to
all potential collaborators solely for research purposes (not-
for-profit/noncommercial) and is protected by the University
of Manchester in the form of a license agreement, which can
be requested online (www.human-development.manchester
.ac.uk/ena/ACCMetricsuserinstructions#Researchlicence
agreement).
Intraepidermal nerve fiber density
A 3 mm punch skin biopsy was taken from the dorsum of
the foot under 1% lidocaine local anesthesia. Skin samples
were immediately fixed in 4% (wt./vol.) paraformaldehyde
for 24 h and then cryoprotected in sucrose for 18 h and cut
into 50 lm sections. Immunohistochemistry was performed
as previously described.15 An image analysis camera Ax-
ioCam MRc (Ziess, Germany) and Leica QWin Standard
V2.4 (Leica Microsystems Imaging, Cambridge, United
Kingdom) were used to quantify IENFD, which is the total
number of nerve fibers per millimeter length of epidermis
(No./mm).
Measurement of neuropathic pain
The McGill Pain Questionnaire was utilized to assess the
quality of the pain using descriptors such as throbbing,
shooting, distressing, and excruciating.16 It contains a total of
78 pain descriptors, which can assess sensory and affective
pain qualities.
Study definition of DPN. DPN was defined according to
the neuropathy disability score (NDS). The maximum score
for the NDS is 10, indicating a complete loss of all sensory
responses and absent reflexes. Scores >2 are abnormal.5,17
Statistical analysis
We performed an unpaired t-test to assess quantitative
variables between groups using GraphPad Prism, version
6.05. All data are expressed as mean – standard error of mean.
A P-value <0.05 was considered statistically significant.
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Receiver operating characteristic (ROC) curve analysis was
used to compare the diagnostic performance of NerveCheck
against objective endpoints for large and small fiber neu-
ropathy using GraphPad Prism, version 6.05. ROC curve
analysis used the area under the curve (AUC) to determine
the optimal sensitivity and specificity of the NerveCheck test.
Results
Clinical data
Of the 74 patients with diabetes, 33 were diagnosed with
and 41 without DPN based on NDS and compared with 70
control subjects. The demographic and clinical characteris-
tics of the subjects with and without DPN and controls are
presented in Table 1. BMI and HbA1c did not differ, but age
(P £ 0.0001), duration of diabetes (P £ 0.0001), and systolic
blood pressure (P £ 0.001) were significantly greater in those
with compared to those without DPN. Using NerveCheck, the
group with DPN had significantly lower scores for VPT
(P £ 0.0001), CPT (P £ 0.0001), and WPT (P £ 0.0001). With
NerveCheck, 44 out of 74 patients with diabetes were de-
tected to have an abnormal vibration or thermal threshold.
The group with DPN also had a significantly lower
PMNCV, sural nerve action potential (SNAP) and conduc-
tion velocity (SNCV) (P £ 0.0001 for all comparisons),
CNFD (P £ 0.0001), and IENFD (P £ 0.001).
Detection of sensory deficits in asymptomatic
and painful neuropathy
The incidence of sensory loss detected by NerveCheck in
the presence and absence of numbness and neuropathic pain
is shown in Table 2. Subjects with diabetes had significantly
higher sensory deficits than the control group (P £ 0.05–
0.0001). The percentage of sensory deficit in subjects without
numbness was 43% (12/48), whereas in subject with numb-
ness it was 65% (30/45). An abnormal vibration or thermal
response was significantly more likely to occur in subjects
with numbness (P £ 0.0001 for all comparisons).
The incidence of sensory deficit in subjects without painful
symptoms was 50% (28/56), whereas in subjects with painful
symptoms it was 78% (14/18). Sensory deficits were signif-
icantly more likely to occur in subjects with pain compared to
those without pain (VPT and WPT, P £ 0.05).
Table 1. Comparison of Clinical Data of Subjects with Diabetes With and Without Diabetic
Peripheral Neuropathy Defined by the Neuropathy Disability Score and Control Subjects
Control subjects No neuropathy Neuropathy
n 70 41 33
Age 41.8 – 1.63*** 44.3 – 2.19 64.1 – 1.79***
Duration of diabetes — 23.3 – 2.03 37.6 – 3.2***
BP-sys (mm Hg) 122.8 – 2.87*** 129.9 – 3.1 147.9 – 4.78**
BMI (kg/m2) 25.8 – 0.79* 27.6 – 0.87 28.4 – 0.8
HbA1c (%) 5.29 – 0.12*** 7.5 – 0.18*** 7.9 – 0.26
HbA1c (mmol/mol) 34.3 – 1.35*** 59.1 – 1.97*** 62.6 – 2.82***
NerveCheck VPT 8.6 – 0.37*** 6.4 – 0.75** 2.1 – 0.6***
NerveCheck CPT 5.9 – 0.07*** 5.5 – 0.22* 3.2 – 0.46***
NerveCheck WPT 4.7 – 0.25*** 5.7 – 0.15** 2.5 – 0.4***
PMNCV (m/s) 49.6 – 0.66*** 42.9 – 0.88*** 36.6 – 1.6**
SNCV (lV) 50.9 – 0.77*** 44.2 – 0.92*** 35.9 – 1.4***
SNAP (m/s) 20.5 – 1.7*** 12.3 – 1.02*** 5.1 – 1.12***
CNFD (No./mm2) 28.8 – 0.92*** 22.9 – 1.3** 14.2 – 1.6***
IENFD (No./mm) 10.9 – 0.8*** 8.05 – 0.7* 3.8 – 0.75**
Data are mean – standard error of the mean, P-values are derived from unpaired t-test: *P £ 0.05, **P £ 0.001, ***P £ 0.0001, The
P-values for comparing those with versus without DPN are in the left column, no DPN versus controls in the middle column, and DPN
versus controls in the right column.
BMI, body mass index; CNFD, corneal nerve fiber density; CPT, cold perception threshold; DPN, diabetic peripheral neuropathy;
HbA1c, glycated hemoglobin; IENFD, intraepidermal nerve fiber density; PMNCV, peroneal motor nerve conduction velocity; SNAP, sural
nerve action potential; SNCV, sural nerve conduction velocity; VPT, vibration perception threshold; WPT, warm perception threshold.
Table 2. Comparison of the NerveCheck Results of Controls, Subjects with Diabetes With and Without
Numbness and With and Without Neuropathic Pain Defined by the McGill Pain Questionnaire
Deficits Controls No numbness Numbness No pain Pain
n 69 28 45 56 18
Signs/Total No. of subjects (%) 4/69 (6) 12/28 (43) 30/45 (67) 28/56 (50) 14/18 (78)
NerveCheck VPT 8.98 – 0.37***, *** 5.4 – 1.02 3.75 – 0.68*** 5 – 0.65*** 2.67 – 0.9*
NerveCheck CPT 5.89 – 0.07***, *** 5.3 – 0.28 4.11 – 0.38*** 4.78 – 0.28*** 3.61 – 0.66
NerveCheck WPT 4.74 – 0.25***, * 5.15 – 0.31** 3.88 – 0.4*** 4.72 – 0.29 3.17 – 0.63*
Data are mean – standard error of the mean, P-values are derived by unpaired t-test: *P £ 0.05, **P £ 0.001, ***P £ 0.0001. The P-values
for controls versus numbness and painful symptoms are in the control column, respectively, controls versus no symptoms are in the no
symptom columns, and present versus absent symptoms are in the symptom columns.
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NerveCheck diagnostic performance against
large and small fiber neuropathy
and neuropathic painful symptoms
The diagnostic performance of NerveCheck was com-
pared to large fiber dysfunction, small fiber loss, and se-
verity of neuropathic pain symptoms using NCS, CCM,
IENFD, and McGill questionnaire, respectively, as refer-
ence methods (Fig. 1). The diagnostic performance ex-
pressed in AUC% using ROC analysis is shown in Table 3.
Vibration perception using NerveCheck had an AUC of
82% (95% confidence interval [CI] 72–93), P < 0.0001 for
SNAP, and 84% (95% CI 75–94), P < 0.0001 for SNCV.
The sensitivity and specificity of VPT against SNCV were
88% (95% CI 67–97) and 82% (95% CI 71–90), respec-
tively. The AUC of the cold perception testing was 78%
(95% CI 66–91), P < 0.0001 for CNFD, and 70% (95% CI
54–87), P = 0.01 for IENFD. The sensitivity and specificity
of CPT against CNFD were 67% (95% CI 44–84) and 85%
(95% CI 75–92), respectively, and against IENFD were
53% (95% CI 28–77) and 82% (95% CI 67–91), respec-
tively. The AUC of WPT was 71% (95% CI 59–84),
P = 0.002 for CNFD, and 69% (95% CI 52–85), P = 0.03 for
IENFD. The sensitivity and specificity of WPT against
CNFD were 67% (95% CI 44–84) and 76% (95% CI 64–
85), respectively, and against IENFD were 56% (95% CI
29–81) and 81% (95% CI 67–91), respectively. For the
severity of neuropathic pain, VPT had an AUC of 70%
(95% CI 57–83), P = 0.006, and a sensitivity and specificity
of 70% (95% CI 57–83) and 68% (95% CI 56–78), re-
spectively. For CPT, the AUC was 63% (95% CI 48–78),
P = 0.07, and the sensitivity and specificity were 40% (95%
CI 19–64) and 84% (95% CI 75–91), respectively. For
WPT, the AUC was 65% (95% CI 50–80), P = 0.04, and the
sensitivity and specificity were 55% (95% CI 32–77) and
73% (95% CI 61–82), respectively.
FIG. 1. ROC curve analysis was used to compare the diagnostic accuracy of the VPT (black line), CPT (dashed line), and
WPT (dotted line) of the NerveCheck in detecting large nerve fiber damage using SNCV, small nerve fiber damage using
CNFD, and IENFD and neuropathic pain using the McGill questionnaire. The gray line is the null value of the ROC curve.
The AUC of the NerveCheck against the SNCV was 84% (95% CI 75–94) for the VPT, 71% (95% CI 58–84) for the CPT,
and 75% (95% CI 63–87) for the WPT, against the CNFD was 76% (95% CI 66–87) for the VPT, 78% (95% CI 66–91) for
the CPT, and 71% (95% CI 59–84) for the WPT, against the IENFD was 60% (95% CI 42–79) for the VPT, 70% (95% CI
54–87) for the CPT, and 69% (95% CI 52–85) for the WPT, and against neuropathic pain was 70% (95% CI 57–83) for the
VPT, 63% (95% CI 48–78) for the CPT, and 65% (95% CI 50–80) for the WPT. AUC, area under the curve; CI, confidence
interval; CNFD, corneal nerve fiber density; CPT, cold perception threshold; IENFD, intraepidermal nerve fiber density;
ROC, receiver operating characteristic; SNCV, sural nerve conduction velocity; VPT, vibration perception threshold; WPT,
warm perception threshold.
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Discussion
In the present study, we have tested the clinical utility of
NerveCheck, an inexpensive ($500) portable (9.5 · 6.1 ·
23.6 cm) device that performs vibration, thermal, and HPT
testing. NerveCheck identifies significantly more sensory
deficits in people with either numbness in the feet or neuro-
pathic pain compared to those without neuropathic symp-
toms. This study has specifically established the diagnostic
accuracy of vibration and thermal testing using NerveCheck,
against other established methods for the diagnosis of large
and small fiber neuropathy. VPT testing optimally identifies
large fiber dysfunction, and CPT testing optimally identifies a
reduction in CNFD and IENFD.
DPN is defined by the presence of symptoms and/or signs
of neuropathy. The diagnosis of DPN is confirmed with a
history of neuropathic symptoms and a careful assessment of
neurological deficits. Identifying early neuropathy is key to
increased awareness, which might prevent the long-term se-
quelae of foot ulceration and amputation as well as helping to
identify those with neuropathic as opposed to nociceptive
pain. Neurological examination and monofilament testing
identify advanced rather than early neuropathy, especially
small fiber damage.17 This study shows that NerveCheck is
an inexpensive device, which can easily perform QST to
identify patients with sensory deficits.
Patients with diabetes for more than 10 years and loss of
sensation in the foot are at high risk of developing foot ul-
cers.18 In a study of 6487 patients with diabetes, the preva-
lence of large fiber neuropathy defined by VPT (‡15 V) was
reported to be 21% (19%–22%) in patients with diabetes
duration <5 years and 37% (35%–39%) in patients with di-
abetes duration >10 years.2 In the United Kingdom Pro-
spective Diabetes Study (UKPDS), the prevalence of severe
large fiber neuropathy defined by VPT (>25 V) was reported
to be 12% in patients with newly diagnosed type 2 diabetes.19
We have shown that VPT assessed using NerveCheck has
high sensitivity and specificity compared to the Neurothesi-
ometer, an established method for VPT testing.9 NerveCheck
provides a simple categorical output, which can be easily
interpreted in relation to the severity of neuropathy and hence
allows risk stratification.
The diagnosis of painful diabetic peripheral neuropathy
(PDPN) is based on a combination of painful neuropathic
symptoms and eliciting sensory deficits and evoked pain8 and
occurs in 20%–30% of patients with diabetes.20,21 Painful
symptoms include burning, tingling, electric shock, or stab-
bing sensations, which are generally worse at night and dis-
turb sleep. We have shown that the prevalence of painful
symptoms assessed using the neuropathy symptom score
(NSS) (>6) and PDPN assessed using the NSS (>6) and NDS
(>2) was 34% and 21%, respectively, in 15,692 community-
based patients with diabetes from Northwest England.21
Furthermore, PDPN is significantly more likely to occur in
patients with more severe DPN.22–24 Indeed, we also show
that NerveCheck is significantly more likely to be abnor-
mal in subjects with painful symptoms compared to those
without pain.
Since QST detects both large and small fiber neuropathy,
its diagnostic performance has been compared to estab-
lished measures of large and small fiber neuropathy using
NCS and IENFD, respectively. A study comparing QST of
mechanical testing and NCS reported 75% sensitivity and
89% specificity for the detection of neuropathy.25 In the
present study, the sensitivity and specificity of VPT using
NerveCheck against SNCV were 88% and 82%, respec-
tively. The sensitivity of thermal testing compared to
IENFD ranges from 36% to 100%.26 Our data show that the
sensitivity and specificity of the CPT using NerveCheck
were 53% and 82% for IENFD, and 67% and 85% for
CNFD, respectively, indicating earlier structural compared
to functional deficits.
In conclusion, the current study shows that NerveCheck,
an inexpensive portable QST device, can identify abnor-
mal vibration and thermal perception thresholds with good
diagnostic utility compared to established tests of large
and small fiber neuropathy and for the severity of neuro-
pathic pain.
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